- Validity of Diagnostic Codes for Identification of Psoriasis Patients in Korea
-
Ham SP, Oh JH, Park HJ, Kim JU, Kim HY, Jung SY, Choi SY, Seol JE, Kim H, Kim MS, Lee UH, Choi M, Park HJ
- KMID: 2471337
- Ann Dermatol.
- 2020 Apr;32(2):115-121.
- doi: 10.5021/ad.2020.32.2.115
BACKGROUND: Recently, the number of nationwide medical researches on psoriasis using the National Health Insurance Service database has been on the rise. However, identification of psoriasis using diagnostic codes alone... -
- CITED
-
- Close
- SHARE
-
- Close
- Characteristics of Pruritus according to Morphological Phenotype of Psoriasis and Association with Neuropeptides and Interleukin-31
-
Park SM, Kim GW, Kim HS, Ko HC, Kim MB, Kim BS
- KMID: 2467194
- Ann Dermatol.
- 2020 Feb;32(1):1-7.
- doi: 10.5021/ad.2020.32.1.1
BACKGROUND: Pruritus is a common symptom in psoriasis. However, few studies have assessed the characteristics of pruritus according to morphological phenotypes of psoriasis. OBJECTIVE: To investigate the characteristics of pruritus according... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Widespread Dermatophytosis during Interleukin-17A Inhibitor Treatment in Psoriasis Patient with Tinea Unguium
-
Lee J, Na N, Park J
- KMID: 2470575
- Korean J Med Mycol.
- 2019 Dec;24(4):100-104.
- doi: 10.17966/JMI.2019.24.4.100
Interleukin-17 (IL-17) is secreted by a class of helper T cells called Th17 cells, which stimulates keratinocytes to secrete proinflammatory mediator and to recruit other inflammatory cells in psoriatic skins.... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Linear Psoriasis along Blashko's Line
-
Kim S, Ko J, Hong D
- KMID: 2470223
- Korean J Dermatol.
- 2019 Dec;57(10):640-642.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- The Effects of Systemic Psoriasis Therapies on the C-Reactive Protein and the Neutrophil-Lymphocyte Ratio
-
Aktaş Karabay E, Aksu Çerman A, Demir D, Kıvanç Altunay I
- KMID: 2461982
- Ann Dermatol.
- 2019 Dec;31(6):601-610.
- doi: 10.5021/ad.2019.31.6.601
BACKGROUND: Currently, no generally accepted laboratory marker for monitorizing the disease activity and therapy response of psoriasis is known. OBJECTIVE: The aim of the study is to evaluate the effects of... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Exfoliative Dermatitis Induced by Phototherapy Secondary to Pustular Psoriasis
-
Park SJ, Jeong GJ, Hong JK, Seo SJ
- KMID: 2465923
- Korean J Dermatol.
- 2019 Nov;57(9):556-557.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Comparative Study of Quality of Life in Patients with Scalp Psoriasis Treated Using Topical Steroid Alone vs. Topical Steroid Combined with Cyclosporine
-
Kim M, Yang S, Kim BR, Youn SW
- KMID: 2465915
- Korean J Dermatol.
- 2019 Nov;57(9):513-518.
BACKGROUND: Scalp psoriasis severely affects patients' quality of life, and patients may occasionally be refractory to topical steroid application. Although systemic therapy combined with topical steroid application is recommended for... -
- CITED
-
- Close
- SHARE
-
- Close
- Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?
-
Kim B, Maverakis , Raychaudhuri SP
- KMID: 2456225
- Ann Dermatol.
- 2019 Oct;31(5):495-501.
- doi: 10.5021/ad.2019.31.5.495
Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Outcomes and Response Pattern of Ustekinumab in Korean Patients with Psoriasis: A Retrospective Single-center Study
-
Oh J, Kim T, Lee MG
- KMID: 2465951
- Korean J Dermatol.
- 2019 Sep;57(8):441-447.
BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory skin disease affecting 2~3% of the worldwide population. Ustekinumab, an IL-12/23p40 inhibitor, is a biologic reported to be effective and safe in treating... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparative Study of Clinical Characteristics according to Therapeutic Efficacy and Drug Survival of Cyclosporine or Methotrexate in Psoriasis Vulgaris
-
Lee HS, Kwon SH, Lee ES
- KMID: 2451491
- Ann Dermatol.
- 2019 Aug;31(4):469-472.
- doi: 10.5021/ad.2019.31.4.469
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Association between Homocysteine Levels and Psoriasis: A Meta-Analysis
-
Kim JE, Lee HJ, Lee JS, Whang KU, Park YL, Lee SY, Kim HJ
- KMID: 2451474
- Ann Dermatol.
- 2019 Aug;31(4):378-386.
- doi: 10.5021/ad.2019.31.4.378
BACKGROUND: Psoriasis is a multifactorial disease associated with an increased risk for metabolic syndrome and cardiovascular diseases. Elevated levels of homocysteine (Hcy) are a marker of cardiovascular risk. Several studies... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Plaque-type Infantile Psoriasis on Both Flank
-
Kim WO, Yoon SD, Ryoo YW, Kim SA
- KMID: 2451594
- Korean J Dermatol.
- 2019 Jun;57(5):282-284.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Docetaxel-Aggravated Psoriasis
-
Yang S, Kim BR, Choi CW, Youn SW
- KMID: 2439078
- Ann Dermatol.
- 2019 Apr;31(2):240-241.
- doi: 10.5021/ad.2019.31.2.240
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Adverse Events after Inappropriate In-Home Ultraviolet Phototherapy: Sunburn and Exacerbation of Psoriasis
-
Park JS, Moon J, Jo SJ
- KMID: 2439071
- Ann Dermatol.
- 2019 Apr;31(2):221-222.
- doi: 10.5021/ad.2019.31.2.221
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Recent medical therapy for psoriasis
-
Youn SW
- KMID: 2441069
- J Korean Med Assoc.
- 2019 Mar;62(3):176-180.
- doi: 10.5124/jkma.2019.62.3.176
Psoriasis is a chronic inflammatory disease. Medical therapy is the mainstay of the management of psoriasis, and the main target of psoriasis treatment is immunological dysregulation. Cyclosporine and methotrexate, the... -
- CITED
-
- Close
- SHARE
-
- Close
- Human Embryonic Stem Cells-Derived Mesenchymal Stem Cells Reduce the Symptom of Psoriasis in Imiquimod-Induced Skin Model
-
Kim CH, Lim CY, Lee JH, Kim KC, Ahn JY, Lee EJ
- KMID: 2441259
- Tissue Eng Regen Med.
- 2019 Feb;16(1):93-102.
- doi: 10.1007/s13770-018-0165-3
BACKGROUND: Mesenchymal stem cells (MSCs) can be used for a wide range of therapeutic applications because of not only their differentiation potential but also their ability to secrete bioactive factors.... -
- CITED
-
- Close
- SHARE
-
- Close
- Morphological Characteristics of Psoriatic Lesions Affect the Accuracy and Reliability of Severity Assessments: Proposal for New Working Criteria for the Psoriasis Area and Severity Index
-
Choi CW, Kim BR, Yang S, Youn SW
- KMID: 2430807
- Ann Dermatol.
- 2019 Feb;31(1):81-83.
- doi: 10.5021/ad.2019.31.1.81
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Real-World Experience with Etanercept Therapy and the Switching Pattern among Korean Patients with Psoriasis after Withdrawal of Etanercept
-
Choi CW, Lee JS, Yu DA, Kim BR, Youn SW
- KMID: 2430800
- Ann Dermatol.
- 2019 Feb;31(1):44-50.
- doi: 10.5021/ad.2019.31.1.44
BACKGROUND: The efficacy and safety of etanercept in the treatment of psoriasis has been proven, and the drug was approved for the treatment of moderate to severe psoriasis. However, there... -
- CITED
-
- Close
- SHARE
-
- Close
- Usefulness of the Psoriatic Arthritis Screening and Evaluation Questionnaire to Monitor Disease Activity in Management of Patients with Psoriasis: Findings from the EPI-PSODE Study
-
Choe YB, Park CJ, Yu DY, Kim Y, Ju HJ, Youn SW, Lee JH, Kim BS, Seo SJ, Yun SK, Park J, Kim NI, Youn JI, Lee SJ, Lee MG, Kim KJ, Ro YS, Song HJ, Shin BS, Ahn SK, Lee JY, Won YH, Jang MS, Kim KH, Kim MH, Kim TY, Choi JH
- KMID: 2430798
- Ann Dermatol.
- 2019 Feb;31(1):29-36.
- doi: 10.5021/ad.2019.31.1.29
BACKGROUND: Psoriasis and psoriatic arthritis (PsA) are included in the group of immune-mediated inflammatory diseases (IMIDs) caused by systemic inflammation; however, indicators for monitoring inflammatory activity in patients with psoriasis,... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Secukinumab for the Treatment of Moderate to Severe Psoriasis in Korea
-
Ha DL, Kim WI, Yang MY, Lee WK, Kim T, Park S, Lee HJ, Kim GW, Kim HS, Ko HC, Kim MB, Kim BS
- KMID: 2433637
- Korean J Dermatol.
- 2019 Jan;57(1):9-14.
BACKGROUND: Secukinumab, a fully human monoclonal antibody that targets interleukin (IL)-17A, which is a central cytokine in the pathogenesis of psoriasis, has emerged as a promising treatment for moderate to... -
- CITED
-
- Close
- SHARE
-
- Close
